By Preeyaporn Srasuebkul

Journal articles

Pearce A; Haas M; Viney R; Haywood P; Pearson S-A; van Gool K; Srasuebkul P; Ward R, 2015, 'Can administrative data be used to measure chemotherapy side effects?', Expert Review of Pharmacoeconomics & Outcomes Research, 15, pp. 215 - 222, http://dx.doi.org/10.1586/14737167.2015.990888

Van Leeuwen MT; Turner JJ; Joske DJ; Falster MO; Srasuebkul P; Meagher NS; Grulich AE; Giles GG; Vajdic CM, 2014, 'Lymphoid neoplasm incidence by WHO subtype in Australia 1982-2006', International Journal of Cancer, 135, pp. 2146 - 2156, http://dx.doi.org/10.1002/ijc.28849

Joshi V; Adelstein B-A; Schaffer A; Srasuebkul P; Dobbins T; Pearson S-A, 2013, 'A Proxy of Cancer Progression in Dispensing Claims: Validation and Performance', PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 22, pp. 221 - 222, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000334876101022&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Langton JM; Srasuebkul P; Buckley NA; Pearson S-A, 2013, 'Prescription Drug Use in the Last 12 Months of Life: Observations in a Cohort of Elderly Patients', PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 22, pp. 352 - 352, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000334876101270&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Joshi V; Adelstein B-A; Srasuebkul P; Dobbins T; Pearson S-A, 2012, 'Estimating Disease Progression in Metastatic Cancer Patients Using Dispensing Data: A Validation Study', PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 21, pp. 169 - 169, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000308131701347&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lu CY; Srasuebkul P; Drew A; Ward RL; Pearson S, 2012, 'Positive spillover effects of prescribing requirements: Increased cardiac testing in patients treated with trastuzumab for HER2+ metastatic breast cancer', Internal Medicine Journal, 42, pp. 1229 - 1235, http://dx.doi.org/10.1111/j.1445-5994.2011.02604.x

Brown D; Hance KW; Rogers C; Sansbury ; Albert P; Murphy G; Laiyemo A; Wang Z; Cross A; Schatzkin A; Danta M; Srasu ; Amin J; Law MG; Breit SN; Lanza E; Brown , 2012, 'Serum Macrophage Inhibitory Cytokine-1 (MIC-1/GDF15): A Potential Screening Tool for the Prevention of Colon Cancer?', Cancer Epidemiology Biomarkers and Prevention, 21, pp. 337 - 346, http://dx.doi.org/10.1158/1055-9965.EPI-11-0786

Puls R; Srasuebkul P; Petoumenos K; Boesecke C; Duncombe CJ; Belloso WH; Molina J; Li L; Avihingsanon A; Gazzard B; Cooper DA; Emery S, 2010, 'Efavirenz versus boosted atazanavir or zidovudine and abacavir in antirectroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study', Clinical Infectious Diseases, Oct 1; 51, pp. 855 - 864

Pujari S; Srasuebkul P; Sungkanuparph S; Lim PL; Kumarasamy N; Chuah J; Kumar R; Oka S; Choi J; Lee M; Phanuphak P; Kamarulzaman A; Lee C; Fujie Z; Ditangco R; Saphonn V; Sirisanthana T; Merati T; Law MG, 2009, 'Patient characteristics and treatment outcome associated with Protease Inhibitor (PI) use in the Asia-Pacific region', Journal of Antivirals & Antiretrovirals, 1, pp. 28 - 035, http://dx.doi.org/10.4172/jaa.1000004

Srasuebkul P; Lim PL; Lee M; Kumarasamy N; Zhou J; Sirisanthana T; Li P; Kamarulzaman A; Oka S; Phanuphak P; Vonthanak S; Merati T; Chen Y; Sungkanuparph S; Tau G; Zhang F; Lee CK; Ditangco R; Pujari S; Choi J; Smith J; Law MG, 2009, 'Short-term clinical disease progression in hiv-infected patients receiving combination antiretroviral therapy: results from the TREAT Asia HIV Observational database', Clinical Infectious Diseases, 48, pp. 940 - 950, http://dx.doi.org/10.1086/597354

Srasuebkul P; Sungkanuparph S; Lim P; Law MG, 2009, 'Universal Prophylaxis, Targeted Prophylaxis, and/or Preemptive Therapy for Opportunistic Infections at the Time of Initiation of Combination Antiretroviral Therapy for Patients with Advanced HIV Infection Reply', Clinical Infectious Diseases, 49, pp. 811 - U170

Pujari SN; Sungkanuparph S; Srasuebkul P; Lim PL; Kumarasamy N; Chuah J; Kumar RN; Phanuphak P, 2008, 'Patient characteristics and treatment outcomes associated with protease inhibitor (PI) use in the Asia-Pacific region', Journal of the International AIDS Society, 11, http://dx.doi.org/10.1186/1758-2652-11-s1-p72

Nuesch R; Ananworanich J; Srasuebkul P; Chetchotisakd P; Prasithsirikul W; Klinbuayam W; Mahanontharit A; Jupimai T; Ruxrungtham K; Hirschel B, 2008, 'Interruptions of tenofovir/emtricitabine based ART in patients with HIV/HBV co-infection', AIDS, 22, pp. 152 - 154

Nuesch R; Ananworanich J; Srasuebkul P; Chetchotisakd P; Prasithsirikul W; Klinbuayam W; Mahanontharit A; Jupimai T; Ruxrungtham K; Hirschel B, 2008, 'Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection', AIDS, 22, pp. 152 - 154

Srasuebkul P; Calmy A; Zhou J; Kumarasamy N; Law MG; Lim P, 2007, 'Impact of drug classes and treatment availability on the rate of antiretroviral treatment change in the TREAT Asia HIV Observational Database (TAHOD).', AIDS Research and Therapy, 4, pp. 18

Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG, 2007, 'Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment', HIV Medicine, 8, pp. 46 - 54

Huffam SE; Srasuebkul P; Zhou J; Calmy A; Saphonn V; Kaldor JM; Ditangco R, 2007, 'Prior antiretroviral therapy experience protects against zidovudine-related anaemia', HIV Medicine, 8, pp. 465 - 471

Boyd MA; Srasuebkul P; Khongphattanayothin M; Ruxrungtham K; Hassink EA; Duncombe CJ; Ubolyam S; Burger DM; Reiss P; Stek M; Lange JM; Cooper DA; Phanuphak P, 2006, 'Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005).', Antiviral Therapy, 11, pp. 223 - 232

Boyd MA; Carr AD; Ruxrungtham K; Srasuebkul P; Bien D; Law MG; Wangsuphachart S; Krisanachinda A; Lerdlum S; Lange J; Phanuphak P; Cooper DA; Reiss P, 2006, 'Changes in body composition and mitochondrial nucleic acid content in patients switched from failed nucleoside analogue therapy to Ritonavir-boosted Indinavir and Efavirenz', Journal of Infectious Diseases, 194, pp. 642 - 650

Nuesch R; Srasuebkul P; Ananworanich J; Ruxrungtham K; Phanuphak P; Duncombe CJ, 2006, 'Monitoring the toxicity of antiretroviral therapy in resource limited settings: a prospective clinical trial cohort in Thailand', Journal of Antimicrobial Chemotherapy, 58, pp. 637 - 644

Boyd MA; Srasuebkul P; Ruxrungtham K; Mackenzie P; Uchaipichat V; Stek M; Lange JM; Phanuphak P; Cooper DA; Udomuksorn W; Miners JO, 2006, 'Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir', Pharmacogenetics and Genomics, 16, pp. 321 - 329

Cardiello P; Hassink EA; Ananworanich J; Srasuebkul P; Samor TM; Mahanontharit A; Ruxrungtham K; Hirschel B; Lange JM; Phanuphak P; Cooper DA, 2005, 'A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection', Clinical Infectious Diseases, 40, pp. 594 - 600

Cardiello P; Srasuebkul P; Hassink EA; Mahanontharit A; Samor TM; Ruxrungtham K; Lange JM; Cooper DA; Phanuphak P, 2005, 'The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy', HIV Medicine, 6, pp. 122 - 128

Ungsedhapand C; Srasuebkul P; Cardiello P; Ruxrungtham K; Ratanasuwan W; Kroon E; Tongtalung M; Juengprasert N; Ubolyam S; Siangphoe U; Emery S; Lange JM; Cooper DA; Phanuphak P, 2004, 'Three-year durability of dual-nucleoside versus triple-nucleoside therapy in a Thai population with HIV infection', JAIDS: Journal of Acquired Immune Deficiency Syndromes, 36, pp. 693 - 701

Ananworanich J; Nuesch R; Teeratakulpisarn S; Srasuebkul P; Chuenyam T; Siangphoe U; Ungsedhapand C; Phanuphak P; Ruxrungtham K, 2003, 'In vivo cell-mediated immunity in subjects with undetectable viral load on protease inhibitor-based versus non-protease inhibitor-based highly active antiretroviral therapy', Journal of Acquired Immune Deficiency Syndrome, 32, pp. 570 - 572

Pothikamjorn SL; Ruxrungtham K; Thampanitchawong P; Fuangthong R; Srasuebkul P; Sangahsapaviriyah A; Suttithavil W; Klaewsongkram J; Parisuthikul V; Viravan T; Rumsaeng V; Kana K; Direkwattanachai C; Kamchaisathien V; Phanupak P, 2002, 'Impact of particulate air pollutants on allergic diseases, allergic skin reactivity and lung function', Asia Pacific Journal of Allergy and Immunology, 20, pp. 77 - 83

Cardiello PG; van Heeswijk RP; Hassink EA; Srasuebkul P; Mahanontharit A; Samor TM; Worarien W; Beijnen JH; Hoetelmans RM; Ruxrungtham K; Cooper DA; Lange JM; Phanuphak P, 2002, 'Simplifying Protease Inhibitor Therapy with Once-Daily Dosing of Saquinavir Soft-Gelatin Capsules/Ritonavir (1600/100 mg): HIVNAT 001.3 Study', JAIDS Journal of Acquired Immune Deficiency Syndromes, 29, pp. 464 - 470, http://dx.doi.org/10.1097/00126334-200204150-00006

Cardiello P; van Heeswijk RP; Hassink EA; Srasuebkul P; Mahanontharit A; Samor TM; Worarien W; Beijnen JH; Hoetelmans RM; Ruxrungtham K; Cooper DA; Lange JM; Phanuphak P, 2002, 'Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100mg):HIVNAT 001.3 study', JAIDS: Journal of Acquired Immune Deficiency Syndromes, 29, pp. 464 - 470

Back to profile page